Carlotta Granchi

List of Publications by Year
in descending order

97 papers	3,617 citations	172207 29 h-index	149479 56 g-index
102 all docs	102 docs citations	102 times ranked	5474 citing authors

#	Article	IF	Citations
1	Estrogen receptors alpha (ERÎ±) and beta (ERÎ²): Subtype-selective ligands and clinical potential. Steroids, 2014, 90, 13-29.	0.8	490
2	Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells. Journal of Medicinal Chemistry, 2011, 54, 1599-1612.	2.9	195
3	Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. Cell Metabolism, 2018, 28, 848-865.e6.	7.2	184
4	Inhibitors of Lactate Dehydrogenase Isoforms and their Therapeutic Potentials. Current Medicinal Chemistry, 2010, 17, 672-697.	1.2	169
5	ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism. European Journal of Medicinal Chemistry, 2018, 157, 1276-1291.	2.6	147
6	Anticancer Agents That Counteract Tumor Glycolysis. ChemMedChem, 2012, 7, 1318-1350.	1.6	137
7	Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. British Journal of Cancer, 2014, 110, 172-182.	2.9	135
8	Application of MM-PBSA Methods in Virtual Screening. Molecules, 2020, 25, 1971.	1.7	105
9	Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways. Oncogenesis, 2014, 3, e102-e102.	2.1	101
10	An update on therapeutic opportunities offered by cancer glycolytic metabolism. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4915-4925.	1.0	78
11	Small-molecule inhibitors of human LDH5. Future Medicinal Chemistry, 2013, 5, 1967-1991.	1.1	76
12	Anticancer agents interacting with membrane glucose transporters. MedChemComm, 2016, 7, 1716-1729.	3.5	66
13	Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. Journal of Hematology and Oncology, 2017, 10, 9.	6.9	65
14	The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies. Seminars in Cancer Biology, 2020, 60, 238-248.	4.3	65
15	N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation. European Journal of Medicinal Chemistry, 2011, 46, 5398-5407.	2.6	64
16	Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death. Scientific Reports, 2015, 5, 15556.	1.6	60
17	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017). Expert Opinion on Therapeutic Patents, 2017, 27, 1341-1351.	2.4	49
18	Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. Organic and Biomolecular Chemistry, 2013, 11, 6588.	1.5	44

#	Article	IF	Citations
19	Dual Targeting of the Warburg Effect with a Glucoseâ€Conjugated Lactate Dehydrogenase Inhibitor. ChemBioChem, 2013, 14, 2263-2267.	1.3	43
20	Identification and characterization of a new reversible MAGL inhibitor. Bioorganic and Medicinal Chemistry, 2014, 22, 3285-3291.	1.4	43
21	Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 1340-1354.	2.9	43
22	Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6923-6927.	1.0	42
23	Structural Optimization of 4-Chlorobenzoylpiperidine Derivatives for the Development of Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 10299-10314.	2.9	42
24	Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor. Journal of Medicinal Chemistry, 2019, 62, 1932-1958.	2.9	42
25	Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase. Phytochemistry, 2015, 116, 262-268.	1.4	40
26	Risks and benefits related to alimentary exposure to xenoestrogens. Critical Reviews in Food Science and Nutrition, 2017, 57, 3384-3404.	5.4	39
27	Structural Evolutions of Salicylaldoximes as Selective Agonists for Estrogen Receptor Î². Journal of Medicinal Chemistry, 2009, 52, 858-867.	2.9	38
28	Bioactive heterocycles containing endocyclic N-hydroxy groups. European Journal of Medicinal Chemistry, 2015, 97, 505-524.	2.6	31
29	Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors. European Journal of Medicinal Chemistry, 2018, 157, 817-836.	2.6	30
30	Estrogen receptor ligands: a patent review update. Expert Opinion on Therapeutic Patents, 2013, 23, 1247-1271.	2.4	29
31	Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer. Journal of Controlled Release, 2018, 281, 1-10.	4.8	29
32	Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. British Journal of Cancer, 2020, 123, 644-656.	2.9	29
33	Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer. Journal of Agricultural and Food Chemistry, 2017, 65, 5639-5649.	2.4	28
34	Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 589-596.	2.5	28
35	Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 1240-1252.	2.5	27
36	Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 956-961.	2.5	27

#	Article	IF	Citations
37	Î±â€Naphthylaminopropanâ€2â€ol Derivatives as BACE1 Inhibitors. ChemMedChem, 2008, 3, 1530-1534.	1.6	26
38	Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7331-7336.	1.0	26
39	Glycoconjugated Metal Complexes as Cancer Diagnostic and Therapeutic Agents. ChemMedChem, 2021, 16, 30-64.	1.6	26
40	Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes. European Journal of Medicinal Chemistry, 2011, 46, 2453-2462.	2.6	25
41	Bioreductively Activated Lysyl Oxidase Inhibitors against Hypoxic Tumours. ChemMedChem, 2009, 4, 1590-1594.	1.6	24
42	Identification of New Fyn Kinase Inhibitors Using a FLAP-Based Approach. Journal of Chemical Information and Modeling, 2013, 53, 2538-2547.	2.5	24
43	The influence of Echinacea purpurea leaf microbiota on chicoric acid level. Scientific Reports, 2019, 9, 10897.	1.6	24
44	Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors. European Journal of Medicinal Chemistry, 2021, 209, 112857.	2.6	24
45	Î±/Î²-Hydrolase Domain (ABHD) Inhibitors as New Potential Therapeutic Options against Lipid-Related Diseases. Journal of Medicinal Chemistry, 2021, 64, 9759-9785.	2.9	24
46	Triazole-substituted N-hydroxyindol-2-carboxylates as inhibitors of isoform 5 of human lactate dehydrogenase (hLDH5). MedChemComm, 2011, 2, 638.	3.5	22
47	Carbazole-containing arylcarboxamides as BACE1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6657-6661.	1.0	22
48	Development and Validation of a Docking-Based Virtual Screening Platform for the Identification of New Lactate Dehydrogenase Inhibitors. Molecules, 2015, 20, 8772-8790.	1.7	22
49	Highly Selective Salicylketoxime-Based Estrogen Receptor Î² Agonists Display Antiproliferative Activities in a Glioma Model. Journal of Medicinal Chemistry, 2015, 58, 1184-1194.	2.9	22
50	Constituents ofPolygala flavescensssp.flavescensand Their Activity as Inhibitors of Human Lactate Dehydrogenase. Journal of Natural Products, 2017, 80, 2077-2087.	1.5	22
51	4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 137-146.	2.5	21
52	Historical perspective of tumor glycolysis: A century with Otto Warburg. Seminars in Cancer Biology, 2022, 86, 325-333.	4.3	21
53	Activators of Sirtuin-1 and their Involvement in Cardioprotection. Current Medicinal Chemistry, 2018, 25, 4432-4456.	1.2	20
54	Salicylketoximes That Target Glucose Transporterâ€...1 Restrict Energy Supply to Lung Cancer Cells. ChemMedChem, 2015, 10, 1892-1900.	1.6	19

#	Article	IF	Citations
55	Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroxyindole class LDH inhibitors as anticancer agents. RSC Advances, 2015, 5, 19944-19954.	1.7	19
56	Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects. Journal of Cellular Physiology, 2019, 234, 15708-15716.	2.0	19
57	Receptor-based virtual screening evaluation for the identification of estrogen receptorÎ²ligands. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 662-670.	2.5	18
58	A Virtual Screening Study for Lactate Dehydrogenase 5 Inhibitors by Using a Pharmacophoreâ€based Approach. Molecular Informatics, 2016, 35, 434-439.	1.4	18
59	Reactive Oxygen Species Synergize To Potently and Selectively Induce Cancer Cell Death. ACS Chemical Biology, 2017, 12, 1416-1424.	1.6	18
60	An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present). Expert Opinion on Therapeutic Patents, 2021, 31, 153-168.	2.4	18
61	ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective. Expert Opinion on Therapeutic Patents, 2022, 32, 731-742.	2.4	18
62	First Examples of H₂S-Releasing Glycoconjugates: Stereoselective Synthesis and Anticancer Activities. Bioconjugate Chemistry, 2019, 30, 614-620.	1.8	16
63	Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance.. Haematologica, 2021, 106, 1163-1166.	1.7	16
64	First-of-its-kind STARD₃ Inhibitor: In Silico Identification and Biological Evaluation as Anticancer Agent. ACS Medicinal Chemistry Letters, 2019, 10, 475-480.	1.3	14
65	New Phenylethanoid Glycosides from Cistanche phelypaea and Their Activity as Inhibitors of Monoacylglycerol Lipase (MAGL). Planta Medica, 2018, 84, 710-715.	0.7	13
66	An Update on Patents Covering Agents That Interfere with the Cancer Glycolytic Cascade. ChemMedChem, 2018, 13, 2251-2265.	1.6	13
67	Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction. Oncoscience, 2020, 7, 76-80.	0.9	13
68	Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 1511-1515.	1.4	12
69	A Guide to PIN1 Function and Mutations Across Cancers. Frontiers in Pharmacology, 2018, 9, 1477.	1.6	12
70	STARD3: A Prospective Target for Cancer Therapy. Cancers, 2021, 13, 4693.	1.7	11
71	New diterpenes from Salvia pseudorosmarinus and their activity as inhibitors of monoacylglycerol lipase (MAGL). FÃ¬toterapÃ¬Ã¢, 2018, 130, 251-258.	1.1	10
72	Discovery of Allosteric Inhibition of Human ATP-Citrate Lyase. Trends in Pharmacological Sciences, 2019, 40, 364-366.	4.0	8

#	Article	IF	Citations
73	BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides. Bioorganic and Medicinal Chemistry, 2010, 18, 7991-7996.	1.4	7
74	New PIN1 inhibitors identified through a pharmacophore-driven, hierarchical consensus docking strategy. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 145-150.	2.5	7
75	Design, Synthesis, and Evaluation of GLUT Inhibitors. Methods in Molecular Biology, 2018, 1713, 93-108.	0.4	6
76	Discovery of Monoacylglycerol Lipase (MAGL) Inhibitors Based on a Pharmacophore-Guided Virtual Screening Study. Molecules, 2021, 26, 78.	1.7	6
77	Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives. Journal of Medicinal Chemistry, 2022, 65, 7118-7140.	2.9	6
78	Monoacylglycerol lipase (MAGL) inhibitors based on a diphenylsulfide-benzoylpiperidine scaffold. European Journal of Medicinal Chemistry, 2021, 223, 113679.	2.6	5
79	Identification of Lactate Dehydrogenase 5 Inhibitors using Pharmacophore- Driven Consensus Docking. Current Bioactive Compounds, 2018, 14, 197-204.	0.2	5
80	The effect of lactate dehydrogenase-A inhibition on intracellular nucleotides and mitochondrial respiration in pancreatic cancer cells. Nucleosides, Nucleotides and Nucleic Acids, 2022, 41, 1375-1385.	0.4	5
81	Three-Dimensional Analysis of the Interactions between hLDH5 and Its Inhibitors. Molecules, 2017, 22, 2217.	1.7	4
82	Synthesis and Biological Evaluation of New Glycoconjugated LDH Inhibitors as Anticancer Agents. Molecules, 2019, 24, 3520.	1.7	4
83	Discovery of a new ATP-citrate lyase (ACLY) inhibitor identified by a pharmacophore-based virtual screening study. Journal of Biomolecular Structure and Dynamics, 2021, 39, 3996-4004.	2.0	4
84	Effect of Tumor Relevant Acidic Environment in the Interaction of a N-hydroxyindole-2-Carboxylic Derivative with the Phospholipid Bilayer. Pharmaceutical Research, 2018, 35, 175.	1.7	3
85	Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction. Oncoscience, 2020, 7, 76-80.	0.9	3
86	New Synthetic Analogues of Natural Polyphenols as Sirtuin 1-Activating Compounds. Pharmaceuticals, 2022, 15, 339.	1.7	3
87	Rational Development of MAGL Inhibitors. Methods in Molecular Biology, 2018, 1824, 335-346.	0.4	2
88	Abstract 3082: Targeting hypoxic pancreatic cancer cells with glucose conjugated lactate dehydrogenase inhibitor NHI-Glc-2. Cancer Research, 2019, 79, 3082-3082.	0.4	2
89	Cyclic Ketoximes as Estrogen Receptorâ€…Î² Selective Agonists. ChemMedChem, 2016, 11, 1752-1761.	1.6	1
90	Abstract 3082: Targeting hypoxic pancreatic cancer cells with glucose conjugated lactate dehydrogenase inhibitor NHI-Glc-2. , 2019, , .		1

#	Article	IF	Citations
91	Biological Activity of Natural and Synthetic Compounds. Molecules, 2022, 27, 3652.	1.7	1
92	Biphenyl-Derivatives Possessing Tertiary Amino Groups as β-Secretase (BACE1) Inhibitors. Letters in Drug Design and Discovery, 2010, 7, 507-515.	0.4	0
93	Phospho-Akt: a potential resistance marker to chemotherapy and therapy-target to restore sensitivity in pancreatic cancer. European Journal of Cancer, 2017, 72, S86.	1.3	0
94	Abstract B53: Targeting metabolic reprogramming in hypoxic models of pancreatic cancer: Preclinical emergence of novel LDH inhibitors, molecular mechanisms underlying their synergistic interaction with gemcitabine.. , 2012, , .		0
95	Abstract 4731: Phospho-akt: a potential resistance marker to chemotherapy and a therapy-target to restore sensitivity in pancreatic cancer. , 2017, , .		0
96	Abstract NT-106: PIN1: A PROMISING TARGET FOR PLATINUM-RESISTANT HIGH GRADE SEROUS OVARIAN CANCER. , 2019, , .		0
97	A carrier free delivery system of a monoacylglycerol lipase hydrophobic inhibitor. International Journal of Pharmaceutics, 2022, 613, 121374.	2.6	0